Immunomodulatory Therapeutic Proteins in COVID‐19: Current Clinical Development and Clinical Pharmacology Considerations

The coronavirus disease 2019 (COVID‐19) pandemic caused by infection with SARS‐CoV‐2 has led to more than 600 000 deaths worldwide. Patients with severe disease often experience acute respiratory distress characterized by upregulation of multiple cytokines. Immunomodulatory biological therapies are...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical pharmacology 2020-10, Vol.60 (10), p.1275-1293
Main Authors: Ji, Ping, Chen, Jianmeng, Golding, Amit, Nikolov, Nikolay P., Saluja, Bhawana, Ren, Yunzhao R., Sahajwalla, Chandrahas G.
Format: Article
Language:English
Subjects:
biologics
clinical pharmacology
Clinical trials
Continuing Education: Review
Coronaviruses
COVID RELATED ARTICLE
COVID-19
Cytokines
Immunomodulation
immunomodulatory
Inflammation
Pandemics
review
Severe acute respiratory syndrome coronavirus 2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The coronavirus disease 2019 (COVID‐19) pandemic caused by infection with SARS‐CoV‐2 has led to more than 600 000 deaths worldwide. Patients with severe disease often experience acute respiratory distress characterized by upregulation of multiple cytokines. Immunomodulatory biological therapies are being evaluated in clinical trials for the management of the systemic inflammatory response and pulmonary complications in patients with advanced stages of COVID‐19. In this review, we summarize the clinical pharmacology considerations in the development of immunomodulatory therapeutic proteins for mitigating the heightened inflammatory response identified in COVID‐19.
ISSN:0091-2700
1552-4604
DOI:10.1002/jcph.1729